<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850406</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-007</org_study_id>
    <nct_id>NCT02850406</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease</brief_title>
  <acronym>HOPE Kids</acronym>
  <official_title>A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of four parts, Parts A, B, C, and D. Part A is a single dose
      pharmacokinetic (PK) study in pediatric participants with Sickle Cell Disease. Part B is a
      multiple dose, safety, exploratory, efficacy, and PK study in adolescent Sickle Cell Disease
      participants who were 12-17 years of age. Part C is a multiple dose, safety, tolerability,
      and PK study, which includes the assessment of hematological effects and the effect on TCD
      flow velocity of voxelotor in pediatric participants with Sickle Cell Disease who are 4 to 17
      years of age. Part D is a multiple dose, safety, tolerability, and PK study, which will
      examine the hematological effects of voxelotor in pediatric participants with Sickle Cell
      Disease who are between 9 months to &lt; 4 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic profile of voxelotor including maximum concentration</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic profile of voxelotor including the time taken to reach the maximum concentration</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Pharmacokinetic profile of voxelotor including the total drug concentration over time</measure>
    <time_frame>Pre-dose to Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change in hemoglobin</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Change in cerebral blood flow as measured by the TAMM TCD velocity</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D: Treatment-Emergent Adverse Events and Serious Adverse Events</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Days 1 - 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Multiple Dose effect on Clinical Measures of Hemolysis</measure>
    <time_frame>Day 1 - Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetic profile of voxelotor including maximum concentration</measure>
    <time_frame>Pre-dose to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetic profile of voxelotor including the time taken to reach the maximum concentration</measure>
    <time_frame>Pre-dose to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetic profile of voxelotor including the total drug concentration over time</measure>
    <time_frame>Pre-dose to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Multiple dose effect on clinical measures of hemolysis</measure>
    <time_frame>Baseline to Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Change in cerebral blood flow</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Pharmacokinetic profile of voxelotor including maximum concentration</measure>
    <time_frame>Pre-Dose to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Pharmacokinetic profile of voxelotor including the time taken to reach the maximum concentration</measure>
    <time_frame>Pre-Dose to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Pharmacokinetic profile of voxelotor including the total drug concentration over time</measure>
    <time_frame>Pre-Dose to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Pharmacokinetic profile of voxelotor including percent Hemoglobin occupancy</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Change in Hemoglobin</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Change in Lactate Dehydrogenase</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Change in Indirect Bilirubin</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Change in Reticulocyte Count</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Time to initial Hemoglobin response</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change in baseline in Hb &gt; 1g/dL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Voxelotor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:
Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)
Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)
Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)
Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voxelotor</intervention_name>
    <description>Part A: Voxelotor will be administered as oral capsules or tablets Part B: Voxelotor will be administered as oral capsules or tablets Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension Part D: Voxelotor will be administered as powder for oral suspension</description>
    <arm_group_label>Voxelotor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female participants with homozygous hemoglobin SS (HbSS) or hemoglobin S beta0
             thalassemia (HbS β0thal)

          2. Age:

               1. Part A - 6 to 17 years of age

               2. Part B - 12 to 17 years of age

               3. Part C - 4 to 17 years of age

               4. Part D - 9 months to &lt;4 years of age

          3. Hydroxyurea (HU) therapy:

               -  Parts A, B, and C: A participant taking hydroxyurea (HU) may be enrolled if the
                  dose has been stable for at least 3 months with no anticipated need for dose
                  adjustment during the study and no sign of hematological toxicity.

               -  Part D: A participant taking HU may be enrolled if the dose has been stable for
                  at least 1 month. Titration to the maximum tolerated dose (MTD) is allowed during
                  the study.

          4. Hemoglobin (HB):

               1. Part A - No restriction

               2. Parts B, C, &amp; D - Hb ≤ 10.5 g/dL

        10. For Part C only: Participants 12 to 17 years of age must have a TCD velocity of ≥ 140
        cm/sec measured anytime during screening.

        Exclusion Criteria:

          1. Any one of the following requiring medical attention within 14 days of signing the
             Informed Consent Form (ICF):

               -  Vaso-occlusive crisis (VOC)

               -  Acute chest syndrome (ACS)

               -  Splenic sequestration crisis

               -  Dactylitis

          2. Requires chronic transfusion therapy

          3. History of stroke or meeting criteria for primary stroke prophylaxis (history of two
             TCD measurements ≥ 200 cm/sec by non-imaging TCD or ≥185 cm/sec by TCDi).

          4. Transfusion within 30 days prior to signing the ICF

        Exclusion Criteria for Part D Only:

        16. Body weight &lt;5 kg for 1 month prior to the screening visit and at the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Tonda, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Tonda, PharmD</last_name>
    <phone>(650) 741-7761</phone>
    <email>mtonda@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aimee Enriquez</last_name>
    <phone>(650) 741-7777</phone>
    <email>aenriquez@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kacie Smith</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>2752</phone_ext>
      <email>kasmith@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Lynne Neumayr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imani Mojerie</last_name>
      <phone>202-476-3578</phone>
      <email>imojerie@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Barnett</last_name>
      <phone>732-135-5976</phone>
      <email>Morgan.Barnett@choa.org</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trecia Dawkins</last_name>
      <phone>312-227-4825</phone>
      <email>TDawkins@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Robert Liem, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Piehet</last_name>
      <phone>225-215-5909</phone>
      <email>allie.piehet@fmolhs.org</email>
    </contact>
    <investigator>
      <last_name>Kacie Sims, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Mehrhof</last_name>
      <phone>816-302-6808</phone>
      <email>amehrhof@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Gerald Woods, MD, FAAP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers - Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>East Carolina University Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Steed</last_name>
      <phone>252-744-2523</phone>
      <email>steedn18@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Beng Fuh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Babb</last_name>
      <phone>267-426-9338</phone>
      <phone_ext>69338</phone_ext>
      <email>babbc@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Kim Smith-Whitley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Martino</last_name>
      <phone>412-692-6467</phone>
      <email>Angela.Martino2@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Cheryl Hillery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Ryan</last_name>
      <phone>901-595-5685</phone>
      <email>kristen.ryan@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Jeremie Estepp, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center AUBMC</name>
      <address>
        <city>Beirut</city>
        <state>Hamrah</state>
        <zip>1107-2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghina Siblany</last_name>
      <phone>9611350000</phone>
      <phone_ext>5595</phone_ext>
      <email>gs57@aub.edu.lb</email>
    </contact>
    <investigator>
      <last_name>Miguel Abboud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rafik Hariri University Hospital (RHUH)</name>
      <address>
        <city>Beirut</city>
        <zip>28337401</zip>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Atwi</last_name>
      <phone>9-610-134-4042</phone>
      <email>lina.atwi@crurhuh.com</email>
    </contact>
    <investigator>
      <last_name>Adlette Inati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Wellings</last_name>
      <email>lucy.wellings2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sara Trompeter, FRCPath, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evelina London Children's Hospital - Guy's and St. Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Kerfoot</last_name>
      <phone>020 7188 7188</phone>
      <phone_ext>86637</phone_ext>
      <email>katherine.kerfoot@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Baba Inusa, FRCPH, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital, Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Simangan</last_name>
      <phone>442035941551</phone>
      <email>Theresa.Simangan@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Telfer, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Lebanon</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

